Explore more
News
Cambridge headquartered global pharmaceutical company AstraZeneca took its spending on China plays in the last month to ...
This trial evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics and clinical activity of AstraZeneca’s ...
Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s Ultomiris (ravulizumab) ...
The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on ...
AstraZeneca, a major pharmaceutical company, has sued Utah’s Attorney General Derek Brown over a recently passed state law ...
Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...
AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...
AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback